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Nod1, a cytosolic protein that senses meso-diaminopimelic acid-
containing ligands derived from peptidoglycan, plays a role in host
responses to invasive bacteria. Here we describe a function for
Nod1, whereby it controls tumor formation. Cell lines derived from
the human breast cancer epithelial cell line MCF-7 were used in a
severe combined immune deficiency (SCID) mouse xenograft
model to characterize a pathway linking Nod1 to the growth of
estrogen-sensitive tumors. In MCF-7 cells, the absence of Nod1
correlates with tumor growth, an increased sensitivity to estrogen-
induced cell proliferation, and a failure to undergo Nod1-depen-
dent apoptosis. Conversely, overexpression of Nod1 in MCF-7 cells
results in inhibition of estrogen-dependent tumor growth and
reduction of estrogen-induced proliferative responses in vitro.
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The innate immune system is composed of families of recep-tors that recognize components of microorganisms, viruses,
or abnormaldamaged host cells. This interaction results in the
initiation of host responses to eliminate and kill invading organ-
isms or to remove atypical host cells (reviewed in refs. 1 and 2).
Members of the Toll-like receptor family (TLR) have been
studied extensively and linked to multiple innate immune re-
sponses. More recently, a second protein family known as the
NLRNodCATERPILLERCLR family has also been linked
to innate immune responses to invasive bacteria (3). The NLRs
have two conserved structural features: a nucleotide-binding
oligomerization domain and leucine-rich repeat region. In con-
trast, the amino-terminal domain has variable structures that act
as effector domains. These domains link activation of NLRNod
family members to downstream signaling pathways and thereby
determine functional responses. Nod1 (caspase recruitment
domain 4; CARD4) and Nod2 (CARD15) were first described
as intracellular receptors for bacterial lipopolysaccharide (LPS)
(4). Now it is apparent that specific activators of Nod1 and Nod2
derive from bacterial peptidoglycan (5–8). Although minimal
structural requirements for the Nod1 and Nod2 activators have
been defined, formal proof of direct binding of activators is
lacking.
The primary function of Nod1 and Nod2 is thought to be as
sensors of invasive bacteria, and mice deficient in Nod1 or Nod2
show increased sensitivity to infection (7, 9). Because of the
presence of one or two CARDs in Nod1 and Nod2, respectively,
these proteins are thought to play a role in apoptosis (10).
However, to date, neither has been implicated in an apoptotic
pathway initiated by a specific and physiologically relevant
activator. Moreover, knockout mice are viable with no obvious
developmental abnormalities (11) so that programmed cell
death during development does not appear to be linked to a
Nod1- or Nod2-dependent function. Nonetheless, it is attractive
to consider a role for Nod1- or Nod2-dependent apoptosis in a
variety of biological responses. In this regard, Nod1 has been
shown to associate with proteins that regulate cell death, and it
appears to enhance the onset and extent of apoptosis. Moreover,
transient expression of Nod1 resulted in a modest enhancement
of caspase-9-induced cell death. Interestingly, overexpression of
Nod1 alone is not sufficient to induce cell death (10). In humans,
mutations in Nod2 are associated with an autoinflammatory
disease known as Blau syndrome (12) and with increased sus-
ceptibility to Crohn’s disease (13, 14). Thus there is a significant
gap in our understanding of the biological settings where Nod1-
or Nod2-dependent apoptosis might be important in the devel-
opment of disease.
Here we have extended our knowledge about the function of
the Nod1 pathway beyond its potential role in responses to
infection. Specifically we provide unanticipated findings that link
the Nod1 pathway to control the growth of the hormone-
sensitive human breast cancer cell line, MCF-7, by using both in
vitro cellular responses as well as data from a xenograft model of
tumor growth in severe combined immune deficiency (SCID)
mice. These data provide evidence that the innate immune
system regulates tumor growth through hitherto unknown
pathways.
Results
Nod1Modulates Apoptosis in MCF-7 Cells.TheMCF-7 breast cancer
epithelial cell line is frequently used as a model to study estrogen
receptor-positive breast cancer (15). We initially used this cell
line to identify genes required for TNF-induced cell death by
using a retroviral-induced mutagenesis approach (16). Retrovi-
ral integration can generate null alleles resulting in diminished
or abolished expression of the target gene. We determined that
one of the resistant clones contained a disrupted Nod1 gene; we
termed this clone MCF-7 C20. The insertion was mapped in the
Nod1 gene between leucine-rich repeat regions 8 and 9. Western
blot analysis with a monoclonal anti-human Nod1 antibody
detected endogenous Nod1 protein in the parental MCF-7 cells
but failed to reveal detectable expression of Nod1 in the C20
clone, suggesting that a functional allele was disrupted (Fig. 1a).
The antibody did not detect the presence of truncated Nod1
mutants, although it was raised against the CARD of Nod1,
suggesting that the Nod1 allele was completely repressed. We
confirmed that the MCF-7 C20 clone was significantly more
resistant to TNF-induced apoptosis than the parent line (Fig.
1b), suggesting that Nod1 acts as a sensitizer in the TNF
pathway and links Nod1 to a ligand-dependent signaling pathway
leading to apoptosis.
Thus here we used the MCF-7 cell line and various clones,
including the Nod1-deficient C20 clone, derived from the pa-
rental cells, to further explore the role of Nod1 in apoptosis. We
first asked whether treatment of cells with a specific Nod1
activator, Ala-Glu-diaminopimelic acid (TriDAP), would in-
duce Nod1-dependent apoptosis. Light microscopic observation
of MCF-7 cells treated with TriDAP in the presence of
cycloheximide (CHX) used to sensitize the cells to apoptosis (17)
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revealed changes associated with apoptosis and not necrosis (Fig.
1c). CHX promotes apoptosis through inhibition of expression of
antiapoptotic molecules such as FLIP (18). The nuclei from
treated cells revealed condensed chromatin as shown by DAPI
staining and also displayed nuclear fragmentation as observed by
TUNEL staining. Further confirmation that TriDAP induces
apoptosis was obtained by using two broad-spectrum caspase
inhibitors, z-VAD-FMK and Boc-D-FMK; both abrogated cell
death (Fig. 1d). MCF-7 cells are known to lack caspase 3 (19),
and, in studies not shown, we determined that expression of
caspase 3 in parental MCF-7 cells or MCF-7 C20 cells did not
change the response patterns to TriDAP. Thus, multiple lines
of evidence show that in MCF-7 cells TriDAP induces a cell
death pathway that is characteristic of apoptosis, and this effect
requires the presence of Nod1 protein.
We next compared the effects of TriDAP on the C20 clone
and several additional cell lines including parental MCF-7 cells
overexpressing human Nod1 (MCF-7 Nod1) and the parental
line transfected with an empty retroviral vector (MCF-7 Blasto;
Fig. 2). MCF-7 cells were treated with TriDAP in the presence
or absence of CHX, and cell death was determined by propidium
iodide (PI) staining and flow cytometry. Exposure of wild-type
cells to TriDAP in the presence of CHX induced 25% cell
death, with no death in cells treated with CHX or TriDAP
alone. The C20 cells were totally resistant to the effects of
TriDAP plus CHX, whereas the same treatment induced
extensive cell death in MCF-7 Nod1 cells after 48 h of treatment.
A control tripeptide, Ala-Glu-meso-diaminopimelic acid
(TriDAP), in which meso-diaminopimelic acid is bound to Glu
in the  position rather than the  position as in TriDAP, did
not induce cell death with or without CHX. Importantly, the
changes in sensitivity to TriDAP shown with MCF-7 C20 cells
were not seen with other proapoptotic stimuli including doxo-
rubicin and camptothecin, where the parental and C20 clones
were equally sensitive to cell death (data not shown). To show
that resistance of C20 cells to TriDAP-induced apoptosis
resulted from the absence of Nod1, we stably expressed human
Nod1 in MCF-7 C20 cells to produce Nod1 sufficient C20 cells
(C20Nod1). Reintroduction of Nod1 restored full sensitivity of
these cells to TriDAP-induced apoptosis (Fig. 2, lower right).
In fact, we observed that overexpression of Nod1 in the C20
clone enhanced sensitivity to TriDAP-induced apoptosis, and,
likewise, stable transfectants of the parental MCF-7 line that
overexpressed Nod1 also showed increase sensitivity to apopto-
sis when Nod1 is activated. Importantly, the ability to comple-
ment the deficient functional responses by expression of Nod1
supports our contention that the phenotype of the MCF-7 C20
cells results from a single defect, namely the failure to express
Nod1.
We also examined a second breast cancer-derived cell line,
SK-BR3, for the presence of a Nod1-dependent apoptotic path-
way. These cells were stably transfected with Nod1, and sensi-
tivity to TriDAP was analyzed. Cells were treated with various
combinations of TNF and TriDAP in the presence or absence
of CHX. The percentage of apoptosis was monitored by PI
staining. As shown in Fig. 3, treatment with TNFCHX for 24 h
was slightly cytotoxic. By contrast, addition of TriDAP dra-
matically enhanced apoptosis of cells exposed to TNFCHX
(80% vs. 40%). We also characterized the activation of different
members of the caspase family and monitored proteolytic pro-
cessing of poly(ADP-ribose) polymerase (PARP) in SK-BR3
cells. PARP and caspases 3, 7, and 8 were cleaved completely in
TNFCHXTriDAP-treated cells. Only partial processing of
PARP was observed in the presence of TNFCHX. The
presence of TriDAP did not enhance TNF-induced apoptosis,
showing again the specificity of TriDAP. In studies not shown
here, we also determined that TriDAP and TNF synergize to
produce cell death in MCF-7 cells, similar to what we observed
with the SK-BR3 cells. In totality, these data indicate that Nod1
regulates apoptotic pathways in multiple cell lines.
Nod2 Activation Does Not Induce Apoptosis in MCF-7 Cells. Nod1 is
closely related to Nod2, and, although Nod1 and Nod2 respond
to different activators, few studies denote functional differences
Fig. 1. Nod1 is involved in TNF-induced apoptosis and triggers an apoptotic
cascade. (a) Nod1 protein is absent in MCF-7 C20 cells. Cell extracts from MCF-7
parental and MCF-7 C20 cells were either immunoprecipitated with a mono-
clonal anti-Nod1 antibody or directly loaded on SDSPAGE and analyzed by
immunoblotting by using anti-Nod1 antibody. (b) MCF-7 C20 cells are more
resistant to TNF-induced apoptosis than parental cells. MCF-7 parental and
MCF-7 C20 cells were treated with TNF (10 ngml), and cell viability was
determined by PI-exclusion assay and flow cytometry analysis. Data are ex-
pressed as mean  SD of four independent experiments. (c) Morphological
changes in TriDAP-treated MCF-7 Nod1 cells. Cells were treated with
TriDAPCHX (2, 4, 6) or CHX alone (1, 3, 5) and stained with DAPI (3, 4) or
TUNEL (5, 6), fixed, and observed under a fluorescence microscope. (d)
TriDAP-induced apoptosis is abolished by broad-spectrum caspase inhibitors.
MCF-7 Nod1 cells were pretreated with Z-VAD-Fmk or Boc-D-Fmk inhibitors
(50 M each) before addition of TriDAPCHX, and cell viability was
measured.
Fig. 2. Nod1 mediates TriDAP-induced cell death. MCF-7 Blasto, MCF-7
Nod1, MCF-7 C20, and MCF-7 C20Nod1 cells were treated with TriDAP or
TriDAP (20 gml each) in the presence or absence of CHX (3 gml). Cell
viability was measured by flow cytometry analysis. Data are expressed as
mean  SD of four independent experiments.









between these proteins. Thus, they both activate NF-B path-
ways, are believed to play a role in sensing intracellular bacteria,
and are coupled to induction of a variety of cytokines. We next
asked whether activation of Nod2 by its specific activator,
muramyl dipeptide (MDP), would initiate apoptosis in parental
MCF-7 cells or in MCF-7 cells overexpressing Nod2 (MCF-7
Nod2). In studies not shown, we used RT-PCR to determine that
the parental MCF-7 cell lines expressed low amounts of mRNA
encoding Nod2. We added TriDAP or MDP in each of these
lines and measured apoptosis (Fig. 4a) and IL-8 production (Fig.
4b). MCF-7 Nod2 cells treated with MDP plus CHX did not
undergo apoptosis. In contrast, TriDAP addition produced cell
death as expected. MDP treatment resulted in IL-8 secretion in
MCF-7 Nod2 cells. It is interesting to note that CHX was
required at low doses to induce IL-8 secretion in response to
TriDAP in MCF-7 Nod1 cells and enhanced IL-8 release in
response to MDP in MCF-7 Nod2 cells. Several mechanisms
have been proposed to explain this effect such as increase in
mRNA stability (20), increase in transcription (21), and stimu-
lation of intracellular signaling pathways (22). Expression of
Nod1 and Nod2 in MCF-7 stable transfectants was confirmed by
immunoblotting (Fig. 4c). In studies not shown, we also deter-
mined that transfection of MCF-7 C20 cells with Nod2 did not
result in apoptosis after addition of either MDP or TriDAP.
Thus it appears that there are distinct cellular pathways that
determine whether activation of the Nod1 and Nod2 pathways
lead to cell death andor to up-regulation of gene activation
pathways.
Nod1 Controls Tumor Formation. We next considered a number of
biological processes where Nod1-dependent apoptotic pathways
might be important. This evaluation included a role in regulating
tumor cell growth where a failure of malignant cells to undergo
cell death leads to tumorigenesis. To examine this possibility, we
used a xenograft model of tumor growth in SCID mice. MCF-7
Blasto, MCF-7 C20, and MCF-7 C20Nod1 were used to induce
tumor growth in SCIDSCID or SCIDNOD mice by s.c.
injection of 3 106 cells into the flanks of female mice. Animals
were scored for tumor formation once a week after injection for
up to 8 weeks. All three cell types grew similar tumors during the
first weeks so that by 15 days after injection there was an
approximate calculated tumor volume of 30 mm3. Surprisingly,
the tumors produced by MCF-7 Blasto and MCF-7 C20Nod1
cells quickly diminished in size and almost disappeared. During
the remaining 40 days of this experiment, the tumors formed
from MCF-7 Blasto and MCF-7 C20Nod1 cells regressed to a
minimally detectable size (10 mm3), whereas MCF-7 C20 cells
produced large round tumors, growing to a maximum volume of
200–270 mm3, at the site of injection (Fig. 5a Left). Thus the
absence of Nod1 allows for tumor growth. Because these studies
are performed in SCID mice, the role of an immune response to
the xenograft is negligible. Further, because the MCF-7 cells
undergo apoptosis in response to TNF, we performed studies
Fig. 3. Synergic activation of apoptosis by TriDAP and TNF in SK-BR3 cells.
SKBR3 Nod1 cells were treated with various combinations of TNF (T),TriDAP
(), TriDAP (), and CHX (C). Cells were harvested 18 h posttreatment and
analyzed for cell viability by PI staining and flow cytometry (Upper). Data are
expressed as mean  SD of six independent experiments. Cell extracts were
also prepared and subjected to immunoblotting with specific antibodies
recognizing proforms and cleaved fragments of PARP and caspases 3, 7, and
8. Results show a representative experiment from three independent
experiments.
Fig. 4. Nod2 does not induce apoptosis in MCF-7 cells. MCF-7 Blasto, MCF-7 Nod1, and MCF-7 Nod2 were treated with TriDAP or MDP (20 gml each) in the
presence or absence of CHX. (a) Cell death was measured by flow cytometry. (b) Cell supernatants were harvested and assayed for IL-8 secretion. Data are
expressed as mean SD of three independent experiments. (c) Expression of Nod1 and Nod2 was confirmed by Western blot analysis by using anti-Myc antibody.
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by using a hamster monoclonal antibody that neutralizes murine
TNF (23). The presence of this antibody did not affect the
outcome of the experiment performed exactly as described
above; no tumors formed when MCF-7 Blasto or MCF-7 Nod1
cells were inoculated, whereas tumors grew when we used
MCF-7 C20 cells (data not shown). The absence of tumors is not
because of a decreased proliferation rate of MCF-7 Blasto and
MCF-7 C20Nod1 cells compared with MCF-7 C20. In studies
not shown, we determined that each of the MCF-7 lines studied
here have identical growth characteristics in tissue culture
conditions and in soft agar colony-forming assays.
In most studies, tumor formation by MCF-7 cells requires
supplementation of estrogens for tumorigenesis in nude mice, even
when cells are inoculated at high concentration. We next decided
to grow all three cell lines inmice that were implantedwith estrogen
pellets (Fig. 5b). As expected, tumors grew in mice injected with
MCF-7 Blasto. Mice injected with MCF-7 C20 grew even larger
tumors in the presence of estrogen pellets. Interestingly, mice that
receivedMCF-7 C20Nod1 did not grow tumors in the presence of
estrogen pellets. These data support a critical role of Nod1 pathway
in tumor growth and suggest that the presence of Nod1 acts as a
brake on estrogen-dependent tumor growth. To obtain additional
support for this contention, we examined the sensitivity of the
MCF-7 cell lines to estrogen-induced proliferation under conditions
where the cells were grown in the absence of estrogen in the culture
medium. Remarkably, we found that theMCF-7 C20 cells undergo
a strong proliferative response to added estrogen, whereas neither
the parental or MCF-7 C20Nod1 lines were stimulated to prolif-
erate under identical conditions (Fig. 5c). The estrogen-induced
proliferation observed with the MCF-7 C20 cells was blocked by
addition of tamoxifen in the culture medium (data not shown).
Finally, we observed that overexpression ofNod1markedly reduced
expression of endogenous estrogen receptor  (ER) without
affecting that of ERK2 used as loading control (Fig. 5d). Similarly,
a decrease in ER expression was also observed in recultured cells
isolated from tumors. These data indicate that Nod1 pathway
influences ER expression levels and therefore the sensitivity of
MCF-7 breast cancer cells to develop tumors.
Discussion
Here we describe findings that provide unanticipated information
about the function of Nod1. Our results support a role for Nod1 in
controlling estrogen responsiveness ofMCF-7 cells, a cellularmodel
for estrogen-sensitive breast cancer tumors. The effect of Nod1 on
estrogen responsiveness was revealed in cell-based assays and, most
importantly, in a xenograft model of MCF-7 dependent tumori-
genesis in SCID mice. This advance in our understanding was a
direct result of obtaining a Nod1-deficient clone of MCF-7 cells
identified in a retrovirus-induced mutagenesis screen where genes
on the TNF-induced apoptosis pathway were being sought. We
characterized a number of MCF-7 derived clones with reduced
sensitivity to TNF-induced apoptosis; one clone termed MCF-7
C20 lacks detectable Nod1 protein, and, most surprisingly, studies
with the parental and C20 clone established that a Nod1-specific
peptidic activator (TriDAP) induces apoptosis. MCF-7 cells have
been shown to be very sensitive to many apoptotic stimuli, and our
data clearly demonstrate that recognition of a motif found in
peptidoglycan by Nod1-induced cell death in physiological condi-
tions. Most importantly, we were able to complement the retroviral
induced mutation in the MCF-7 C20 clone by reintroduction of
Nod1 into this clone.
The potential role of Nod1 in host responses to invasive
bacteria has been identified by others (7–9). Our data now adds
another function to Nod1, namely its ability to regulate the
growth of estrogen-sensitive tumors formed by the MCF-7 cells
in a xenograft model performed in SCID mice. Multiple lines of
evidence support our contention that there is a link between
Nod1 and estrogen sensitivity of MCF-7 cells. In the absence of
Nod1 or when the Nod1 pathway is disabled by other means,
MCF-7 cells formed large tumors in SCID mice even in the
absence of estrogens. By contrast, endogenous Nod1 or overex-
pressed Nod1 abrogated the capacity of these cells to develop
tumors. RIP2RICK is a protein kinase that functions as a
downstream mediator of Nod1 signaling (24–26). In data not
shown here, we showed that the parental MCF-7 cells stably
expressing the dominant negative form of RIP2 (RIP2 CARD)
are similar to the C20 clone insofar as being able to grow tumors
in SCID mice and being highly responsive to estrogen-induced
Fig. 5. The presence of Nod1 prevents tumor growth in SCID mice. (a) MCF-7 Blasto, MCF-7 C20, and MCF-7 C20Nod1 cells (3106 cells per mouse) were injected
in the flanks of female SCID mice. Tumor size was measured once a week, and volume was determined according to the formula (W2 L)2. Each line represents
tumor growth of 1 mouse (n 4). (b) Mice were implanted with estrogen pellets before injection with MCF-7 cells, and tumor size was determined. Mean SD
are shown for 8 mice. (c) MCF-7 C20 and MCF-7 RIP2CARD cells show a higher sensitivity to estrogens. Indicated MCF-7 cells were exposed to increasing
concentration of 17-estradiol and pulsed with [3H]thymidine, and cell growth was determined by liquid scintillation. Data are representative of at least three
independent experiments. (d) Down-regulation of endogenous ER by Nod1. Total protein extracts from MCF-7 Blasto, MCF-7 C20, and MCF-7 C20Nod1 cells
and from cells isolated from tumors were analyzed by immunoblotting by using antibody against ER and ERK2 as loading control.









cell proliferation, further demonstrating an important role of the
Nod1 pathway in the control of tumor growth. Studies donemore
than two decades ago by Krueger et al. (27) showed that muramyl
peptides containing diaminopimelic acid accumulate in the
human urine, suggesting that commensal f lora may provide a
source of Nod1 activators. These data may warrant reexamina-
tion in view of the findings reported here to determine whether
there are circulating levels of Nod1 activators present in the
SCID mice.
Other factors that might control tumor growth, such as the
participation of the host immune system, are ruled out by the use
of SCID mice or the coadministration of neutralizing anti-
murine TNF antibody. Further, we observed that simply block-
ing apoptosis in the MCF-7 line by stable expression of c-FLIP
CLARP did not lead to tumor growth consistent with a key role
for other Nod1-dependent events (data not shown). Thus, our
data support the contention that Nod1 acts as a brake on various
aspects of estrogen responsiveness in MCF-7 cells. The crosstalk
between these two pathways is highlighted by the fact that Nod1
blocked estrogen-induced cell proliferation. Our studies of Nod1
in this setting open up the possibility of a more complete
understanding of the molecular mechanisms involved. For ex-
ample, in additional studies (J.d.S.C. and R.J.U., unpublished
data), we have established a link between Nod1 and the COP9
complex (28). Others have proposed a role for one or more
components of the COP9 complex in tumor growth and control
of ER degradation (29); future studies using the models we
have established will allow this idea to be explored further.
In summary, these data provide insights into the physiological
functions of Nod1 by linking it to pathways that control tumor
cell growth. There are no reports about enhanced tumor devel-
opment in mice with a deletion of the Nod1 gene. In fact there
are very limited data on the Nod1 knockout mice and essentially
all published work has been performed with human Nod1. The
present report provides a mechanism that links innate immunity
and tumor growth. Future studies will allow an assessment of the
relevance of the pathway characterized here in human breast
cancer and perhaps other hormone-sensitive malignancies and
may lead to the development of unique therapeutic approaches
to stabilize or eradicate hormone-sensitive tumors.
Materials and Methods
Retroviral Mutagenesis Screening.A clone of an MCF-7 cell, which
exhibited a spontaneous survival rate of1 in 106, was randomly
mutated with retrovirus pDisrup. We infected 5  106 cells with
pDisrup virus and obtained 104 blasticidin-resistant clones.
Blasticidin-resistant clones and control parental MCF-7 cells
were treated with TNF (100 ngml) for 48 h. The clones were
regrown and picked up 2 weeks later. Although 50 TNF resistant
clones were obtained from the retrovirus mutated cells, no clone
was recovered from the control parental MCF-7 cells. Total
RNA was isolated from each of the clones by use of TRIzol
reagent (Invitrogen). The portion of the endogenous gene that
was fused with the blasticidin gene was amplified by the 3 rapid
amplification of cDNA ends (RACE) technique. Reverse tran-
scription was performed with the primer RT 5-CCAGTGAGC
AGA GTG ACG AGG ACT CGA GCT CAA GC[T]17-3. A
nested PCR was performed with the resulting reverse transcrip-
tion product with the following primers: P1Q1 (5-AAA GCG
ATA GTG AAG GAC AGT GA-3 and 5-CCA GTG AGC
AGAGTGACG-3) and P2Q2 (5-TGC TGC CCT CTGGTT
ATG TGT GG-3 and 5-GAG GAC TCG AGC TCA AGC-3).
P1 and P2 are located on the balsticidin gene, whereas Q1 and
Q2 are on the anchor sequence of RT. The PCR products of
3RACE and RT-PCR were directly sequenced.
Cell Culture. Human breast cancer cell lines MCF-7 and SK-BR3
were maintained in DMEM supplemented with 10% FBS, 2 mM
glutamine, 100 unitsml penicillin, and 10 gml streptomycin.
To determine the effects of 17-estradiol (Calbiochem), cells
were cultured in phenol red-free DMEM supplemented with 5%
charcoal-stripped FCS. Cells were seeded in 96-well plates with
various concentration of 17-estradiol (E2) for 24 h and pulsed
with [3H]thymidine [1 Ci (1 Ci  37 GBq) per well; MP
Biomedicals, Irvine, CA]. Cells were harvested on glass fiber
filters, and radioactivity was measured by liquid scintillation.
Reagents. Anti-PARP and anti-caspases 3, 7, and 9 were from
Cell Signaling Technology (Beverly, MA). M2 anti-FLAG
monoclonal antibody was from Sigma. Polyclonal rabbit anti-
Myc antibody was from Upstate Biotechnology (Lake Placid,
NY), and monoclonal anti-Myc 9E10 was from Santa Cruz
Biotechnology. CHX was obtained from Sigma. Monoclonal
anti-Nod1 antibody was produced in our laboratory and raised
against the CARD. The broad spectrum caspase inhibitors
z-VAD-FMK and Boc-D-FMK were purchased from Calbio-
chem. Human recombinant TNF was purchased from R & D
Systems. MDP was purchased from Bachem. TriDAP (Ala-
Glu-meso-DAP) and TriDAP (Ala-Glu-meso-DAP) were
chemically synthesized by AnaSpec (San Jose, CA).
Mammalian Expression Constructs and Site-Directed Mutagenesis.
Human FLAG-Nod1, FLAG-Nod2, and cDNAs were obtained
from G. Nun˜ez (University of Michigan Medical School).
Cell Viability Assays. PI exclusion assay. Cells were stimulated for
indicated times. Subsequently, cells were harvested, washed
twice in FACS buffer (PBS containing 1% FCS and 0.1%NaN3),
and resuspended in PI-containing FACS buffer (4 gml). The
extent of cell death was analyzed with a FACSCalibur flow
cytometer (Becton Dickinson) by counting 10,000 cells.
DAPI staining. MCF-7 cells were plated in chamber slides and
stimulated for 2 days. Apoptotic nuclei were stained with 1
gml DAPI (Sigma). Cells were fixed in 4% paraformaldehyde
and examined by fluorescence microscopy.
TUNEL staining. Cells were treated with TriDAP and apoptotic
nuclei were monitored by TUNEL assay according to manufac-
turer’s instruction (Roche Applied Sciences, Indianapolis, IN).
3,3 dihexyloxacarbocyanine iodide [DiOC6 (3)] staining. Mitochandrial
membrane potential (	m) was evaluated by staining of cells
with 40 nM DiOC6 (3) (Molecular Probes) (stock solution of 1
M in ethanol) for 20 min at 37°C. The fluorescence emitted by
cells was analyzed by FACS.
Western Blot Analysis. Cells were washed extensively and lysed in
lysis buffer containing 50 mM Hepes, 100 mM NaCl, 2 mM
EDTA, 10% glycerol, 1% Nonidet P-40, 14 M pepstatin A, 100
M leupeptin, 3 mM benzamidine, 1 mM PMSF, 1 mM sodium
pyrophosphate, 10 mM sodium orthovanadate, 100 unitsml
aprotinin, and 100 mM sodium fluoride. Cell lysates were
separated on SDSPAGE and transferred to poly(vinylidene
difluoride) membranes.
IL-8 ELISA. Concentration of IL-8 in the culture supernatants of
transfected HeLa cells was measured by ELISA by using 96-well
Immunlon plates (Dynatech). ELISA was performed by using
the mAb MAB208 for capture and a biotinylated polyclonal
rabbit anti-human IL-8 Ab (R & D Systems) followed by
streptavidin horseradish peroxidase for detection.
Xenograft Model. MCF-7 Blasto, MCF-7 C20, and MCF-7 C20
Nod1 were trypsinized, washed once with PBS, and resuspended
to a concentration of 1.5  107 cells per ml. Two hundred
microliters of each suspension was inoculated s.c. in the flanks
of female SCID mice. Tumor size was assessed once a week, and
tumor volume was calculated.
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